Related Experiment Video
Updated: Aug 20, 2026
Large-Scale Preparation of Synovial Fluid Mesenchymal Stem Cell-Derived Exosomes by 3D Bioreactor Culture
Published on: July 26, 2022
Exosome therapy for knee osteoarthritis: a network meta-analysis based on rat models
Yixiang Zhao1, Haochuan You1, Xiuyuan Wang1
1Department of Orthopedics, Lanzhou University Second Hospital, Lanzhou, 730030, China.
Objective:
To compare the therapeutic effects of exosomes from different cell sources and doses in rat knee osteoarthritis models using network meta-analysis, and to identify potential optimal strategies for preclinical optimization and clinical hypothesis generation.
Methods:
A systematic search of PubMed, Web of Science, Embase, and Scopus identified 27 eligible randomized controlled trials (456 rats). Traditional random-effects meta-analysis and frequentist network meta-analysis were conducted. Treatments were ranked using SUCRA values.
Results:
A total of 27 studies were included, comprising 456 rats. Traditional meta-analysis revealed that exosome therapy significantly reduced joint cartilage histopathological damage (reduced OARSI score: SMD = -3.78, 95% CI: -4.76, -2.80), promoted type II collagen synthesis (SMD = 3.41, 95% CI: 1.87, 4.95), and suppressed the expression of the inflammatory cytokine IL-1β (SMD = -3.26, 95% CI: -4.08, -2.44). Network meta-analysis further indicated that under high-dose conditions (≥100 μg), exosomes derived from human amniotic fluid stem cells (hAFSCs-Exo) and human umbilical cord mesenchymal stem cells (hUCMSCs-Exo) ranked highest in relative efficacy for improving the OARSI score. hUCMSCs-Exo also demonstrated the most potent anti-inflammatory effect by reducing IL-1β. Overall, exosome therapy exhibited a dose-related trend in efficacy, with high-dose transplantation showing higher probabilistic SUCRA rankings across most outcome measures. However, assessment of publication bias revealed marked asymmetry; after trim-and-fill correction, the effect size for type II collagen expression decreased from SMD = 3.41 to 1.26, suggesting that the magnitude of the treatment effect may have been overestimated. This overestimation reduces the certainty of the observed treatment effects. Despite the presence of publication bias and methodological limitations, the main conclusions remained statistically robust after trim-and-fill correction.
Conclusion:
Current evidence from rat models suggests that exosome therapy may substantially ameliorate the pathological progression of KOA, with exosomes derived from early developmental tissues, particularly hAFSCs-Exo and hUCMSCs-Exo, showing favorable chondroprotective and anti-inflammatory effects in the probabilistic ranking when administered at high doses. Nevertheless, the findings from publication bias and trim-and-fill analyses indicate that the existing effect sizes are likely overestimated. These results require confirmation in larger-scale, methodologically more rigorous preclinical studies.
Insights
Exosome therapy shows promise for knee osteoarthritis (KOA) in rat models, with high-dose exosomes from specific stem cells offering the best results. However, potential overestimation of treatment effects warrants further rigorous preclinical investigation.
Area of Science:
- Regenerative Medicine
- Osteoarthritis Therapeutics
- Extracellular Vesicles
Background:
- Knee osteoarthritis (KOA) is a degenerative joint disease with limited effective treatments.
- Exosomes, nano-sized vesicles derived from cells, are emerging as potential therapeutic agents.
- Understanding the optimal cell source and dosage of exosomes is crucial for effective KOA treatment.
Purpose of the Study:
- To compare the therapeutic efficacy of exosomes from various cell sources and doses in rat KOA models.
- To identify optimal preclinical strategies for exosome therapy in KOA.
- To generate hypotheses for future clinical applications of exosome therapy for KOA.
Main Methods:
- Systematic literature search of major scientific databases (PubMed, Web of Science, Embase, Scopus).
- Inclusion of 27 randomized controlled trials involving 456 rats.
- Application of traditional random-effects meta-analysis and frequentist network meta-analysis.
- Ranking of treatment efficacy using SUCCRA values.
Main Results:
- Exosome therapy significantly reduced cartilage damage (OARSI score), promoted type II collagen synthesis, and suppressed IL-1β expression.
- High-dose exosomes (≥100 μg) from human amniotic fluid stem cells (hAFSCs-Exo) and human umbilical cord mesenchymal stem cells (hUCMSCs-Exo) showed the highest efficacy for improving OARSI scores.
- hUCMSCs-Exo exhibited the most potent anti-inflammatory effects.
- Publication bias was detected, and trim-and-fill correction suggested potential overestimation of treatment effects, particularly for type II collagen synthesis.
Conclusions:
- Exosome therapy demonstrates significant potential to ameliorate KOA pathological progression in preclinical rat models.
- Exosomes from early developmental tissues (hAFSCs-Exo, hUCMSCs-Exo) show promising chondroprotective and anti-inflammatory effects at high doses.
- Findings suggest potential overestimation of treatment effects due to publication bias; further rigorous preclinical studies are needed for confirmation.
